Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center 
Welcome,         Profile    Billing    Logout  
 26 Diseases   7 Trials   7 Trials   195 News 


123»
  • ||||||||||  Journal:  Drugs for asthma. (Pubmed Central) -  Nov 19, 2024   
    No abstract available No abstract available
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial initiation date:  Inhaled Ciclesonide Study in Preterm Infants (clinicaltrials.gov) -  Nov 12, 2024   
    P1,  N=30, Not yet recruiting, 
    No abstract available Initiation date: Nov 2024 --> Feb 2025
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    New P1 trial:  Inhaled Ciclesonide Study in Preterm Infants (clinicaltrials.gov) -  Sep 20, 2024   
    P1,  N=30, Not yet recruiting, 
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports. (Pubmed Central) -  Aug 4, 2024   
    Multidrug therapy is effective because of the differing mechanisms of action of these drugs, and it may also mitigate the emergence of drug-resistant SARS-CoV-2 strains. The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl).
  • ||||||||||  niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Trial primary completion date:  PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) -  Mar 17, 2024   
    P2/3,  N=5000, Recruiting, 
    The medicines were lopinavir/ritonavir (Kaletra), bamlanivimab (monoclonal antibody), glycopyrrolate-formoterol (Bevespi), ciclesonide (Alvesco), famotidine (Pepcid), and diphenhydramine (Benadryl). Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Enrollment open, Trial completion date, Trial primary completion date:  Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) -  Aug 10, 2022   
    P4,  N=110, Recruiting, 
    Trial primary completion date: Jul 2023 --> Jul 2024 Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
  • ||||||||||  niclosamide nasal spray (UNI91103) / UNION Therap, Institut Pasteur Korea, Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Enrollment change, Trial completion date, Trial primary completion date:  PROTECT-V: PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (clinicaltrials.gov) -  Mar 8, 2022   
    P2/3,  N=5000, Recruiting, 
    Communicated by Ramaswamy H. Sarma. N=1500 --> 5000 | Trial completion date: Mar 2022 --> Oct 2024 | Trial primary completion date: Dec 2021 --> Jul 2023
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) -  Feb 4, 2022   
    P2/3,  N=412, Completed, 
    N=1500 --> 5000 | Trial completion date: Mar 2022 --> Oct 2024 | Trial primary completion date: Dec 2021 --> Jul 2023 Recruiting --> Completed | N=820 --> 412 | Trial completion date: Feb 2022 --> Oct 2021 | Trial primary completion date: Jan 2022 --> Oct 2021
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (clinicaltrials.gov) -  Feb 2, 2022   
    P2,  N=98, Active, not recruiting, 
    Recruiting --> Completed | N=820 --> 412 | Trial completion date: Feb 2022 --> Oct 2021 | Trial primary completion date: Jan 2022 --> Oct 2021 Recruiting --> Active, not recruiting | N=446 --> 98 | Trial completion date: May 2022 --> Jan 2022 | Trial primary completion date: Dec 2021 --> Aug 2021
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Journal:  Assessment of the effectiveness of early treatment in SARS-CoV-2 infection (Pubmed Central) -  Dec 28, 2021   
    The use of the assessed drugs should take into account the time of onset of SARS-CoV-2 infection and the severity of the disease course, including comorbidities. The presented analysis of the effectiveness of early treatment in patients infected with SARS-CoV-2 requires further clinical trials.
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Phase classification, Trial primary completion date:  Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma (clinicaltrials.gov) -  Dec 17, 2021   
    P4,  N=110, Not yet recruiting, 
    The presented analysis of the effectiveness of early treatment in patients infected with SARS-CoV-2 requires further clinical trials. Phase classification: P=N/A --> P4 | Trial primary completion date: Jun 2023 --> Jan 2024
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Journal:  Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks. (Pubmed Central) -  Nov 17, 2021   
    Superior anti-inflammatory and antioxidative stress effects characterized by significant decrease (p< .0001) in inflammatory cytokines IL-4 and 13, serum IgE levels, malondialdehyde (MDA), nitric oxide (NO), TNF-α, and activated nuclear factor-κB (NF-κB) activity were obvious with concomitant increase in superoxide dismutase (SOD) activity. Histological examination with inhibition of inflammatory cell infiltration in the respiratory tract was correlated well with observed biochemical improvement.
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial termination:  Inhaled Ciclesonide for Outpatients With COVID19 (clinicaltrials.gov) -  Aug 18, 2021   
    P2/3,  N=215, Terminated, 
    This method would be applicable to the analysis of other inhalable pharmaceutical products whose sample preparation requires complicated procedures, as well as to the analysis of general pharmaceutical products for profiling impurities. Active, not recruiting --> Terminated; could not meet target enrolment
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial completion date, Trial primary completion date:  COVERAGE: Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (clinicaltrials.gov) -  Aug 18, 2021   
    P2/3,  N=820, Recruiting, 
    Active, not recruiting --> Terminated; could not meet target enrolment Trial completion date: Aug 2021 --> Feb 2022 | Trial primary completion date: Aug 2021 --> Jan 2022
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Trial completion:  A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19 (clinicaltrials.gov) -  Jun 24, 2021   
    P2,  N=68, Completed, 
    Trial completion date: Aug 2021 --> Feb 2022 | Trial primary completion date: Aug 2021 --> Jan 2022 Recruiting --> Completed
  • ||||||||||  Alvesco (ciclesonide) / Covis Pharma, Teijin, Korea University Medical Center
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Inhaled Ciclesonide for Outpatients With COVID19 (clinicaltrials.gov) -  Jun 22, 2021   
    P2/3,  N=215, Active, not recruiting, 
    Recruiting --> Completed Recruiting --> Active, not recruiting | N=454 --> 215 | Trial completion date: Mar 2021 --> Aug 2021 | Trial primary completion date: Feb 2021 --> Jul 2021